Multi-scale models reveal hypertrophic cardiomyopathy MYH7 G256E mutation drives hypercontractility and elevated

Insights

The MYH7 G256E mutation causes hypertrophic cardiomyopathy by increasing myosin availability and altering crossbridge cycling, leading to hypercontractility and increased mitochondrial respiration. This study elucidates genotype-phenotype relationships in genetic cardiovascular diseases.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Genetics of Heart Disease

Background:

  • Over 200 mutations in the beta-myosin heavy chain (MYH7) gene are linked to hypertrophic cardiomyopathy (HCM).
  • Genotype-phenotype relationships are complex due to variable penetrance and altered myosin function, particularly for rare variants like MYH7 G256E.
  • Understanding the functional impact of low-penetrant mutations is crucial for diagnosing and treating HCM.

Approach:

  • Developed a multi-scale collaborative pipeline to analyze myosin function from protein to tissue levels.
  • Investigated the MYH7 G256E mutation's effects on myosin structure, function, and cellular responses using CRISPR-edited human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).
  • Compared functional alterations caused by G256E with previously studied MYH7 mutations.

Key Points:

  • The MYH7 G256E mutation disrupts the S1 head transducer region, increasing myosin availability for contraction by 50.9%.
  • G256E-mutated myofibrils and hiPSC-CMs exhibit hypercontractility, characterized by faster tension development and altered crossbridge cycling kinetics.
  • Transcriptomic and metabolic profiling revealed upregulated mitochondrial genes and increased respiration, indicating altered bioenergetics in G256E-mutated cells.

Conclusions:

  • The MYH7 G256E mutation induces structural instability, leading to multi-scale hypercontractility via increased myosin recruitment and altered crossbridge cycling.
  • Hypercontractility is associated with enhanced mitochondrial respiration, while cellular hypertrophy is modest under physiological stiffness.
  • The multi-scale platform provides a valuable tool for elucidating genotype-phenotype relationships in genetic cardiovascular diseases.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
17
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
18